- NEWS AND VIEWS
Immune treatment tackles chronic obstructive pulmonary disease
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Nature 621, 476-477 (2023)
doi: https://doi.org/10.1038/d41586-023-02517-5
References
Hurst, J. R. et al. Eur. J. Intern. Med. 73, 1–6 (2020).
Bhatt, S. P. et al. N. Engl. J. Med. 389, 205–214 (2023).
Schett, G., McInnes, I. B. & Neurath, M. F. N. Engl. J. Med. 385, 628–639 (2021).
Brusselle, G. G. & Koppelman, G. H. N. Engl. J. Med. 386, 157–171 (2022).
Singh, D. et al. Am. J. Respir. Crit. Care Med. 206, 17–24 (2022).
Hammad, H. & Lambrecht, B. N. Cell 184, 1469–1485 (2021).
Ordovas-Montanes, J. et al. Nature 560, 649–654 (2018).
Dwyer, D. F. et al. Sci. Immunol. 6, eabb7221 (2021).
Ma, J. et al. Sci. Immunol. 6, eabg6356 (2021).
Ahmad, H., Jahn, N. & Jaiswal, S. Annu. Rev. Med. 74, 249–260 (2023).
Philips, R. L. et al. Cell 185, 3857–3876 (2022).
Competing Interests
J.V.F. is a member of the Scientific Advisory Board of Connect Biopharma. Connect is developing drugs that target type 2 cytokines as a treatment for lung and skin diseases. J.V.F. is also a founder, consultant and shareholder in Aer Therapeutics. Aer is developing mucolytic drugs for the treatment of mucus-obstructive lung diseases. R.M.L. is a member of the Scientific Review Board of Genentech. Genentech is developing inhibitors of the type 2 inflammation cascade for the treatment of lung disease.